Annals of Oncology 14:85-90, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer
1 Dipartimento di Medicina Sperimentale e Patologia, Università degli Studi di Roma ‘La Sapienza’, Rome; 2 Dipartimento di Patologia e Medicina di Laboratorio, Università degli Studi di Parma, Parma, Italy
Received 28 March 2002; revised 27 May 2002. accepted 8 July 2002
Background:
It has been suggested that progression of superficial bladder cancer may be regulated at the molecular level by a typical pattern of expression of genes involved in apoptosis. Recently LIVIN, belonging to the inhibitors of apoptosis (IAP) family, has been found to be expressed in most solid tumors, where its expression is suggested to have prognostic significance. No data are available concerning the significance of LIVIN in the progression of bladder tumors.
Patients and methods:
In the present paper we used RT–PCR to investigate the expression of LIVIN isoforms 
and ß, SURVIVIN, BCL-X and BCL-2/BAX expression ratio both in normal and tumoral bladder tissues, and correlated their expression with the emergence of early relapses in a follow-up of 4 years. This study shows that only the isoform of LIVIN, which is not expressed in normal bladder tissue, is expressed in a proportion of tumors with a high risk of relapse.
Results:
LIVIN was found in 7/30 patients (23%), SURVIVIN in 9/30 (30%), BCL-2/BAX ratio >1 in 16/30 (53%), BCL-2/BAX expression ratio <1 in 14/30 (46.6%) and BCL-X, only in isoform BCL-XL, in 11/30 (36.6%). When we evaluated the dependence between each gene expression and relapse free time of patients, we found that LIVIN, high BCL-2/BAX ratio and BCL-XL, but not SURVIVIN, reached statistical significance in order to predict relapses.
Conclusions:
Our findings suggest that LIVIN may be involved in the progression of superficial bladder cancer and used as a marker of early recurrence; while the expression of SURVIVIN cannot be used to identify patients with high risk of relapse.
Key words: BCL-2/BAX, BCL-X, bladder cancer, LIVIN, relapse, SURVIVIN
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Abd-Elrahman, K. Hershko, T. Neuman, B. Nachmias, R. Perlman, and D. Ben-Yehuda The Inhibitor of Apoptosis Protein Livin (ML-IAP) Plays a Dual Role in Tumorigenicity Cancer Res., July 1, 2009; 69(13): 5475 - 5480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, Q. Zhang, B. Liu, M. Han, and B. Shan Challenge and promise: roles for Livin in progression and therapy of cancer Mol. Cancer Ther., December 1, 2008; 7(12): 3661 - 3669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Als, L. Dyrskjot, H. von der Maase, K. Koed, F. Mansilla, H. E. Toldbod, J. L. Jensen, B. P. Ulhoi, L. Sengelov, K. M.E. Jensen, et al. Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4407 - 4414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Choi, Y. K. Hwang, K. W. Sung, S. H. Lee, K. H. Yoo, H. L. Jung, H. H. Koo, H.-J. Kim, H. J. Kang, H. Y. Shin, et al. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia Blood, January 15, 2007; 109(2): 471 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chang and A. D. Schimmer Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy Mol. Cancer Ther., January 1, 2007; 6(1): 24 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hariu, Y. Hirohashi, T. Torigoe, H. Asanuma, M. Hariu, Y. Tamura, K. Aketa, C. Nabeta, K. Nakanishi, K. Kamiguchi, et al. Aberrant Expression and Potency as a Cancer Immunotherapy Target of Inhibitor of Apoptosis Protein Family, Livin/ML-IAP in Lung Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1000 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Douglas, H. Fiegler, A. Rowan, S. Halford, D. C. Bicknell, W. Bodmer, I. P. M. Tomlinson, and N. P. Carter Array Comparative Genomic Hybridization Analysis of Colorectal Cancer Cell Lines and Primary Carcinomas Cancer Res., July 15, 2004; 64(14): 4817 - 4825. [Abstract] [Full Text] [PDF]
|
|